Opthalmology National Electronic Age-related Macular Degeneration (AMD) Audit: Feasibility report

Reports | Published: 22 Mar 2018

This feasibility study was commissioned by HQIP as part of a National Ophthalmology Audit with The Royal College of Ophthalmologists as the Audit Provider. Following feedback from NHSE minor amendments were made to this report in advance of its release in March 2018.

The annual incidence in the UK of the “wet” or neovascular (NvAMD) form of AMD has been estimated as 39,700 new cases per year, a figure projected to rise by a third by 2020.

NICE-approved treatments for “wet” NvAMD have included both ranibizumab (technology appraisal guidance 155) and aflibercept (technology appraisal guidance 294) on the basis of their clinical and cost-effectiveness.

In 2015−16, ranibizumab was second and aflibercept was fourth in the list of medicines with positive NICE technology appraisals on which the NHS spent most money, between them accounting for a total of around £450 million expended. Although some of these costs relate to use for other licensed indications, a sizable majority would have been for treatment of NvAMD and it is accepted that the cost impact of the use of these drugs for NvAMD is high.

Don’t miss out. Sign up to be notified when this resource is updated and to receive updates about other related quality improvement resources, events and news from HQIP. Or you can  .

By continuing you agree to receive emails with updates and other information from HQIP and you are confirming you are over the age of 13.

Please read our privacy policy to understand how HQIP uses the information you provide, your use of HQIP’s website and your interaction with the marketing emails to improve the relevance of the communications we send you. You can unsubscribe at any time.

I have read and agree with the contents of the privacy policy.

Opthalmology National Electronic Age-related Macular Degeneration (AMD) Audit: Feasibility report